Ключевые слова:
артериальная гипертензия, гипертрофия левого желудочка, ремоделирование сердца, эхокардиография, электрокардиография, ожирение, дислипидемия, сердечно-сосудистый риск.Библиографические ссылки
1. McEvoy J.W., McCarthy C.P., Bruno R.M. et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. European Heart Journal. 2024.2. Mancia G., Kreutz R., Brun-ström M. et al. 2023 ESH Guidelines for the management of arterial hypertension. Journal of Hypertension. 2023.
2. Unger T., Borghi C., Charchar F. et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75 (6):1334–1357.
3. Verdecchia P., Angeli F., Borgioni C. et al. Prognostic value of left ventricular hypertrophy in essential hypertension. Journal of the American College of Cardiology.
4. Fagard R.H., Celis H., Thijs L. et al. Regression of left ventricular mass by antihypertensive treatment and cardiovascular risk reduction.
5. Dahlöf B., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study.
6. Pierdomenico S.D., Lapenna D., Bucci A. et al. Cardiovascular risk reduction associated with regression of left ventricular hypertrophy in hypertension.
7. Costanzo P., Perrone-Filardi P., Petretta M. et al. Calcium channel blockers and regression of left ventricular hypertrophy: an updated meta-analysis.
8. Zhang L., Zhang S., Sun X. et al. Association between left ventricular hypertrophy and cardiovascular outcomes in patients with hypertension.
9. Hu S., et al. Prognostic significance of left ventricular hypertrophy and its regression in patients with arterial hypertension.11. Kim H., et al. Association between left ventricular hypertrophy and cardiovascular outcomes in patients with hypertension.
